Premenstrual dysphoric disorder: diagnostics and therapy

The objective of the paper is to evaluate the efficacy of ultra-low dose oral contraceptive containing drospirenone and a selective serotonin reuptake inhibitor in the therapy of premenstrual dysphoric disorder. Materials and Methods. The study included 43 women with premenstrual dysphoric disorder who were divided into 2 groups: Group 1 (n=22) included women who needed contraception and took an ultra-low dose of oral contraceptive containing drospirenone. Group 2 (n=21) included patients who took 20 mg of fluoxetine in the morning (once every 3 days). Effectiveness of treatment was evaluated with statistical processing of the questionnaires before the therapy, in 3 and in 6 months after treatment onset. Results. In 6 months after therapy onset, the condition of patients improved. However, Group 1 demostrated the following main symptoms: depression (5 patients/22.7 %), aggression (5 patients/22.7 %), anxiety (4 patients/18.2 %), self-control disorder (4 patients/18.2 %) (p